Recognizing and treating depression in children and adolescents

American Journal of Health-System Pharmacy

Volumn 63, Issue 3, 2006, Pages 233-243

  Dopheide, Julie A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Adolescents; Antidepressants; Cognitive therapy; Depression; Diagnosis; Fluoxetine; Patient information; Pediatrics; Suicides; Toxicity

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ATOMOXETINE; CAFFEINE; CITALOPRAM; ESCITALOPRAM; ESZOPICLONE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MACROLIDE; MIRTAZAPINE; NEFAZODONE; NEUROLEPTIC AGENT; PAROXETINE; PHENYTOIN; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ZOLPIDEM;

ABDOMINAL PAIN; ADOLESCENT; AGGRESSION; AGITATION; ANHEDONIA; ANOREXIA; BEHAVIOR THERAPY; BULLYING; CHILD; CHILDHOOD INJURY; CLINICAL TRIAL; COGNITIVE THERAPY; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EUPHORIA; FAMILY COUNSELING; FATIGUE; GENETIC SUSCEPTIBILITY; HEADACHE; HEART MUSCLE CONDUCTION DISTURBANCE; HOSTILITY; HUMAN; HYPERTENSION; HYPOMANIA; IMPULSIVENESS; INCIDENCE; INCREASED APPETITE; INSOMNIA; IRRITABILITY; MACULOPAPULAR RASH; MANIA; MENTAL INSTABILITY; NAUSEA; PATIENT EDUCATION; PR INTERVAL PROLONGATION; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; QRS COMPLEX PROLONGATION; QT PROLONGATION; REVIEW; RHINITIS; RISK BENEFIT ANALYSIS; SIDE EFFECT; STRESS; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE ATTEMPT; THORAX PAIN; UPPER ABDOMINAL PAIN; URINE INCONTINENCE; VISUAL HALLUCINATION; VOMITING;

EID: 31544479074     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050264     Document Type: Review

References (65)

1. Food and Drug Administration. FDA issues public health advisory on cautions for use of antidepressants in adults and children. www.fda.gov/bbs/ topics/answers/2004/ANS01283.html (accessed 2004 Mar 12).
2. Food and Drug Administration. FDA statement on recommendations of the psychopharmacologic drugs and pediatric advisory committees. www.fda.gov/bbs/topics/news/2004/NEW01116.html (accessed 2005 May 16).
3. Vedantam S. Fewer kids prescribed drugs for depression. www.washingtonpost.com/ac2/wp-dyn/A55371-2005Feb1 (accessed 2005 Jun 11).
4. Delate T, Gelenberg AJ, Simmons VA et al. Trends in the use of antidepressants in a national sample of commercially insured pediatric patients, 1998 to 2002. Psychiatr Serv. 2004; 55:387-91.
5. Brent DA. Antidepressants and pediatric depression: the risk of doing nothing. N Engl J Med. 2004; 351:1598-601.
6. American College of Neuropsychopharmacology. Preliminary report of the task force on SSRIs and suicidal behavior in youth. www.acnp.org/exec_summary. pdf (accessed 2004 Feb 4).
7. Emslie GJ, Heiligenstein JH, Wagner KD et al. Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry. 2002; 41:1205-15.
8. March J, Silva S, Petrycki S et al. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression. JAMA. 2004; 292:807-20.
9. Compton SN, March JS, Brent D et al. Cognitive-behavioral psychotherapy for anxiety and depressive disorders in children and adolescents: an evidence-based medicine review. J Am Acad Child Adolesc Psychiatry. 2004; 43:930-59.
10. Olfson M, Gameroff MJ, Marcus SC et al. Outpatient treatment of child and adolescent depression in the United States. Arch Gen Psychiatry. 2003; 60:1236-42.
11. Richardson LP, DiGiuseppe D, Christakis DA et al. Quality of care for Medicaid-covered youth treated with antidepressant therapy. Arch Gen Psychiatry. 2004; 61:475-80.
12. Birmaher B, Brent DA, Benson RS. Summary of the practice parameters for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry. 1998; 37:1234-8.
13. Costello EJ, Mustillo S, Erkanli A et al. Prevalence and development of psychiatric disorders in childhood and adolescence. Arch Gen Psychiatry. 2003; 60:837-44.
14. Saluja G, Iachan R, Scheidt PC et al. Prevalence of and risk factors for depressive symptoms among young adolescents. Arch Pediatr Adolesc Med. 2004; 158:760-5.
15. Lewinsohn PM, Rohde P, Seeley JR et al. Natural course of adolescent major depressive disorder in a community sample: predictors of recurrence in young adults. Am J Psychiatry. 2000; 157:1584-91.
16. Luby JL, Heffelfinger AK, Mrakotsky C et al. Preschool major depressive disorder: preliminary validation for developmentally modified DSM-IV criteria. J Am Acad Child Adolesc Psychiatry. 2002; 41:928-37.
17. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fourth edition, text revision. Arlington, VA: American Psychiatric Press; 2000:345-428.
18. National Institute of Mental Health. www.nimh.nih.gov/publicat/ depression.cfm (accessed 2005 Mar 1).
19. Geller B, Zimmerman B, Williams M et al. Bipolar disorder at prospective follow-up of adults who had prepubertal major depressive disorder. Am J Psychiatry. 2001; 158:125-7.
20. Wagner KD. Diagnosis and treatment of bipolar disorder in children and adolescents. J Clin Psychiatry. 2004; 65(suppl 15):30-4.
21. Martin A, Young C, Leckman JF et al. Age effects on antidepressant- induced manic conversion. Arch Pediatr Adolesc Med. 2004; 158:773-80.
22. Kowatch RA, Fristad M, Birmaher B et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2005; 44:213-35.
23. Leonard HL, March J, Rickler KC et al. Pharmacology of the selective serotonin reuptake inhibitors in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1997; 36:725-36.
24. Ten Eick AP, Nakamura H, Reed MD. Drug-drug interactions in pediatric psychopharmacology. Pediatr Clin North Am. 1998; 45:1233-64.
25. Williamson DE, Birmaher B, Axelson DA et al. First episode of depression in children at low and high familial risk for depression. J Am Acad Child Adolesc Psychiatry. 2004; 43:291-7.
26. Fergusson DM, Beautrais AL, Horwood LJ. Vulnerability and resiliency to suicidal behaviours in young people. Psychol Med. 2003; 33:61-73.
27. Botteron KN, Raichle ME, Drevets WC et al. Volumetric reduction in left subgenual prefrontal cortex in early onset depression. Biol Psychiatry. 2002; 51:342-4.
28. Rosenberg DR, Mirza Y, Russell A et al. Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry. 2004; 43:1146-53.
29. Birmaher B, Dahl RE, Williamson DE et al. Growth hormone secretion in children and adolescents at high risk for major depressive disorder. Arch Gen Psychiatry. 2000; 57:867-72.
30. Vythilingam M, Heim C, Newport J et al. Childhood trauma associated with smaller hippocampal volume in women with major depression. Am J Psychiatry. 2002; 159:2072-80.
31. Rosso IM, Cintron CM, Steingard RJ et al. Amygdala and hippocampus volumes in pediatric major depression. Biol Psychiatry. 2005; 57:21-6.
32. Caspi A, Sugden K, Moffitt TE et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003; 301:386-9.
33. Nobile M, Cataldo MG, Giorda R et al. A case-control and family-based association study of the 5-HTTLPR in pediatric-onset depressive disorders. Biol Psychiatry. 2004; 56:292-5.
34. Anderson RN. Deaths: leading causes for 2000. Natl Vital Stat Rep. 2002; 50:1-85.
35. Sourander A, Helstela L, Haavisto A et al. Suicidal thoughts and attempts among adolescents: a longitudinal 8-year follow-up study. J Affect Disord. 2001; 63:59-66.
36. Rohde P, Clarke GN, Mace DE et al. An efficacy/effectiveness study of cognitive-behavioral treatment for adolescents with comorbid major depression and conduct disorder. J Am Acad Child Adolesc Psychiatry. 2004; 43:660-8.
37. Olfson M, Shaffer D, Marcus SC et al. Relationship between antidepressant medication treatment and suicide in adolescents. Arch Gen Psychiatry. 2003; 60:978-82.
38. Gibbons RD, Hur K, Bhaumik DK et al. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry. 2005; 62:165-72.
39. Grunebaum MF, Ellis SP, Li S et al. Antidepressants and suicide risk in the United States, 1985-1999. J Clin Psychiatry. 2004; 65:1456-62.
40. Oquendo MA, Malone KM, Ellis SP et al. Inadequacy of antidepressant treatment for patients with major depression who are at risk for suicidal behavior. Am J Psychiatry. 1999; 156:190-4.
41. Weissman MM, Wolk S, Wichramaratne P et al. Children with prepubertal-onset major depressive disorder and anxiety grown up. Arch Gen Psychiatry. 1999; 56:794-801.
42. Jayson D, Wood A, Kroll L et al. Which depressed patients respond to cognitive-behavioral treatment? J Am Acad Child Adolesc Psychiatry. 1998; 37:35-9.
43. Klein DN, Lewinsohn PM, Seeley JR et al. A family study of major depressive disorder in a community sample of adolescents. Arch Gen Psychiatry. 2001; 58:13-20.
44. Santor DA, Kusumakar V. Open trial of interpersonal therapy in adolescents with moderate to severe major depression: effectiveness of novice IPT therapists. J Am Acad Child Adolesc Psychiatry. 2001; 40:236-40.
45. Emslie GJ, Walkup JT, Pliszka SR et al. Nontricyclic antidepressants: current trends in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1999; 38:517-28.
46. Wagner KD, Ambrosini P, Rynn M et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA. 2003; 290:1033-41.
47. Keller MB, Ryan ND, Strober M et al. Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2001; 40:762-72.
48. Wagner KD, Robb AS, Findling RL et al. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. Am J Psychiatry. 2004; 161:1079-83.
49. Campo JV, Perel J, Lucas A et al. Citalopram treatment of pediatric recurrent abdominal pain and comorbid internalizing disorders: an exploratory study. J Am Acad Child Adolesc Psychiatry. 2004; 43:1234-42.
50. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med. 2001; 344:1279-85.
51. Hughes CW, Emslie GJ, Crismon ML et al. The Texas Children's Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. J Am Acad Child Adolesc Psychiatry. 1999; 38:1442-54.
52. Riggs PD, Leon SL, Mikulich SK et al. An open trial of bupropion for ADHD in adolescents with substance use disorders and conduct disorder. J Am Acad Child Adolesc Psychiatry. 1998; 37:1271-8.
53. www.wellbutrin.com (accessed 2005 Jun 11).
54. Kratochvil CJ, Wagner KD, Emslie G et al. Pharmacological management of treatment-resistant pediatric depression. J Am Acad Child Adolesc Psychiatry. 2005; 44:198-200.
55. Mandoki MW, Tapia MR, Tapia MA et al. Venlafaxine in the treatment of children and adolescents with major depression. Psychopharmacol Bull. 1997; 33:149-54.
56. Wilens TE, Spencer TJ, Biederman J et al. Case study: nefazodone for juvenile mood disorders. J Am Acad Child Adolesc Psychiatry. 1997; 36:481-5.
57. Nefazodone. www.fda.gov/cder/drug/infosheets/patient/nefazodonePIS.pdf (accessed 2005 Aug 15).
58. Haapasalo-Pesu KM, Vuola T, Lahelma L et al. Mirtazapine in the treatment of adolescents with major depression: an open-label, multicenter pilot study. J Child Adolesc Psychopharmacol. 2004; 14:175-84.
59. Daly JM, Wilens T. The use of tricyclic antidepressants in children and adolescents. Pediatr Clin North Am. 1998; 45:1123-35.
60. Mezzacappa E, Steingard R, Kindlon D et al. Tricyclic antidepressants and cardiac autonomic control in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1998; 37:52-9.
61. Brent DA, Holder D, Kolko D et al. A clinical psychotherapy trial for adolescent depression comparing cognitive, family, and supportive therapy. Arch Gen Psychiatry. 1997; 54:877-85.
62. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA. 2004; 292:338-43.
63. Geller B, Cooper TB, Chestnut EC et al. Preliminary data on the relationship between nortriptyline plasma level and response in depressed children. Am J Psychiatry. 1986; 143:1283-6.
64. Lake MB, Birmaher B, Wassick S et al. Bleeding and selective serotonin reuptake inhibitors in childhood and adolescence. J Child Adolesc Psychopharmacol. 2000; 10:35-8.
65. Wyeth Pharmaceuticals, Inc. Effexor in formation page. www.effexor.com (accessed 2005 Aug 15).